Format

Send to

Choose Destination
Immunotherapy. 2011 Nov;3(11):1303-16. doi: 10.2217/imt.11.123.

Otelixizumab in the treatment of type 1 diabetes mellitus.

Author information

1
Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium.

Abstract

Anti-CD3 antibodies have been demonstrated in both animal and human studies to be able to reverse autoimmune diseases; for example Type 1 diabetes. Not only does treatment with anti-CD3 antibodies result in the removal of pathogenic T cells but evidence suggests that a state of operational tolerance can be induced through the effects on regulatory T cells. The clinical use of anti-CD3 antibodies has been hampered by their safety profile. However, the introduction of humanized, nonmitogenic, aglycosylated anti-CD3 antibodies, such as otelixizumab, and promising results reported in newly-diagnosed patients with Type 1 diabetes, have renewed the interest for these antibodies in the treatment of autoimmune diseases.

PMID:
22053883
DOI:
10.2217/imt.11.123
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center